This new CPB states that brexanolone (Zulresso) injection is considered medically necessary for the treatment of postpartum depression in adult women (18 years of age or older) when criteria are met. This new CPB states that more than one brexanolone infusion per pregnancy/childbirth is considered experimental and investigational.